-
2023
-
Regeneron is off to CHAPLE as FDA starts pozelimab review
-
FDA Accepts Two sNDAs for Merck’s Prevymis
-
Moderna announces interim results from Phase 3 safety and immunogenicity trial of mRNA-1010, vaccine candidate.
-
Chiesi Group’s Lamzede Gets FDA Approval for Rare Genetic Disorder
-
COVID-19 Infection Can Increase a Patient’s Risk of New-Onset Diabetes
-
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARIᵀᴹ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
-
Maze Therapeutics to Present Phase 1 Results from First-in-Human Trial Evaluating MZE001 as a Potential Oral Treatment for Pompe Disease
-
HHS pilots seek to complement IRA in lowering drug costs
-
Biocon and Viatris Draw Complete Response Letter for Bevacizumab BLA
-
Kinnate Biopharma Gets Fast Track Status for Bile Duct Cancer Candidate